VeriTeQ Life Sciences, Inc. is a medical technology company dedicated to the development and commercialization of miniaturized, leadless implantable sensors designed for continuous hemodynamic monitoring. Leveraging proprietary wireless power and communication technology, the company’s platform sensors are intended to measure central venous pressure (CVP) in real time, offering clinicians a novel tool for managing fluid balance, heart failure and other critical care applications. VeriTeQ’s approach eliminates transcutaneous leads, reducing infection risk and improving patient comfort.
The company’s initial product candidate, known as the Helius Model H sensor, is a percutaneously implanted device that resides within the superior vena cava. Powered externally via a wearable patch, the sensor transmits pressure data to a user interface that can be integrated into electronic health records or remote patient monitoring systems. By providing continuous CVP readings, Helius aims to enable earlier intervention, optimize diuretic therapy and support decision-making in both inpatient and outpatient settings.
VeriTeQ’s technology is backed by a growing intellectual property portfolio, including patents covering wireless charging, hermetic encapsulation of electronics and high-precision pressure transduction. The company is advancing its sensor platform through pre-clinical studies and is preparing for regulatory filings with the U.S. Food and Drug Administration and comparable agencies overseas. Collaborations with academic medical centers and contract research organizations are helping to validate the safety and performance of the Helius system ahead of first-in-human trials.
Headquartered in Florida with research operations in Canada, VeriTeQ serves hospitals, specialty clinics and remote care providers across North America, with plans to expand distribution into Europe and Asia-Pacific. The leadership team comprises seasoned executives and engineers with experience in medical devices, regulatory affairs and clinical development. Under the guidance of CEO Sariq Raza and a board of directors with extensive healthcare industry backgrounds, VeriTeQ is positioning its platform to address a growing need for minimally invasive, continuous hemodynamic monitoring solutions.
AI Generated. May Contain Errors.
Free VTEQ Stock Alerts